NCT02170064View on ClinicalTrials.gov

Pharmacokinetics, Efficacy and Tolerability of BIA 2-093

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions
Epilepsy
Interventions
DRUG

BIA 2-093 (Eslicarbazepine acetate)

Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route

Trial Locations (1)

041914

"Clinica de Neurologie Pediatrica, Spitalul Alexandru Obregia", Bucharest

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT02170064 - Pharmacokinetics, Efficacy and Tolerability of BIA 2-093 | Biotech Hunter | Biotech Hunter